🇺🇸 Boostrix-IPV in United States

20 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bradycardia — 2 reports (10%)
  2. Diverticulum — 2 reports (10%)
  3. Dizziness — 2 reports (10%)
  4. Exposure During Pregnancy — 2 reports (10%)
  5. Large Intestinal Stenosis — 2 reports (10%)
  6. Lung Consolidation — 2 reports (10%)
  7. Maternal Exposure Before Pregnancy — 2 reports (10%)
  8. Maternal Exposure During Pregnancy — 2 reports (10%)
  9. Renal Cyst — 2 reports (10%)
  10. Urinary Tract Infection — 2 reports (10%)

Source database →

Boostrix-IPV in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Boostrix-IPV approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Boostrix-IPV in United States?

St George's, University of London is the originator. The local marketing authorisation holder may differ — check the official source linked above.